Sanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but the company hopes new data could help it gather momentum. The French ...

The products covered include Admelog, Lantus, Toujeo, Apidra and any biosimilar of those products that Sanofi markets in the U.S., and the new pricing will be available to all consumers ...

There is good news for Mainers who rely on insulin according to our media partners WMTW. Maine Attorney General Aaron Frey announced a settlement agreement Tuesday with Sanofi-Aventis U.S. following ...

Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the company’s pricing of insulin products.

One of the key priorities for Witz is a successful launch for Lantus follow-up Toujeo, which hinges on whether Sanofi can make a compelling case for switching patients currently taking Lantus to ...

12 February 2018, Sanofi India announced the launch of its new insulin product Toujeo. Toujeo is a once-daily, long-acting basal analog insulin that improves glycemic control in adults with type 1 ...

Sanofi India share price gains were likely driven by its quarterly results performance and the dividend announcements, even though stock gave away most gains as the stock market crashed and Sensex ...

Long-acting insulin helps people with diabetes maintain normal blood sugar levels throughout the day. Unlike short-acting insulin, it never peaks, keeping an even sugar level in your blood. When ...

Ozempic (semaglutide) is a prescription drug used for certain conditions in people with type 2 diabetes. Ozempic is given as an injection under your skin. Ozempic can be prescribed for adults with ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.